IRB #

STUDY00019633

Title

[NCI CIRB] S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Principal Investigator

Tomasz Beer

Study Purpose

This 2-arm randomized study designed to explore if standard systemic therapy plus definitive treatment of the primary cancer improves disease control and survival over standard systemic therapy alone.

Medical Condition(s)

Metastatic Prostate Cancer

Eligibility Criteria

Adenocarcinoma of the prostate
Intact prostate with no prior local therapy
Radiographic evidence of disease progression in bone or soft tissue
Castration resistant (Testosterone less than 50 ng/dL)

Age Range

18 - 110

Healthy Volunteers Needed

No

Duration of Participation

Up to 8 years and 7 months.

Minors Included

No

Contact

Rachel Slottke

Sponsor

SWOG

Recruitment End

03/31/2023

Compensation Provided

No


Go Back